ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2025
Multimodal Artificial Intelligence-Based Virtual Biopsy for Diagnosing Abdominal Lavage Cytology-Positive Gastric Cancer.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Two decades of progress in gastric cancer peritoneal metastasis: a bibliometric perspective on molecular mechanisms and therapeutic innovations.Frontiers in oncology · 2025Pooled it
- Spectral focused imaging enables enhanced colorectal adenoma detection: a multicenter, parallel randomized controlled trial.BMC medicine · 2026Trial
- Characterization of acquired capecitabine resistance in MKN-45 gastric cancer cells reveals preserved apoptotic sensitivity.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2026Article
- Non-invasive prediction of occult peritoneal metastasis (OPM) in gastric cancer using logistic regression and random forest integrative models with CT radiomics and clinical parameters: machine learning prediction of gastric OPM.Journal of gastrointestinal oncology · 2026Article
- The Lymph Node Ratio as a Predictive Biomarker for Individualized Benefit from Adjuvant Chemotherapy in Gastric Cancer: A Retrospective Cohort and Causal Machine Learning Study.Journal of gastrointestinal cancer · 2026Article
- Differential expression of the C-Myc gene in intestinal-type and diffuse-type gastric cancer and its clinical significance.BMC gastroenterology · 2026Article
- Study of phosphorylated ribosomal protein S6 (pS6) in the clinical outcomes of patients undergoing hepatectomy for metastatic colorectal cancer.World journal of surgical oncology · 2026Article
- An LSCC-specific R-loop-related model predicts prognosis and neoadjuvant immunotherapy response and identifies EIF5A2-mediated tumor-immune crosstalk.World journal of surgical oncology · 2026Article
- Artificial intelligence models: transforming early diagnosis and precise treatment of gastrointestinal cancers.Molecular cancer · 2026Review
- Transforming Gastric Biopsy Diagnostics: Integrating Omics Technologies and Artificial Intelligence.Biomedicines · 2026Article
- Risk factors and nomogram for early mortality in young patients with non-metastatic gastric cancer.Translational cancer research · 2026Article
- Multimodal digital biopsy for preoperative prediction of occult peritoneal metastasis in gastric cancer.NPJ digital medicine · 2026Article
- Probiotic supplementation as a nutritional strategy for the prevention and management of sarcopenia in older adults.Frontiers in cellular and infection microbiology · 2026Article
- An albumin-based immune-nutritional score for predicting complete response, organ preservation, and toxicity after neoadjuvant PD-1-based therapy in low rectal cancer.Frontiers in immunology · 2026Article
- Baseline thyroid function and treatment-emergent thyroid dysfunction predict pathological response and survival after neoadjuvant PD-1 inhibitor plus platinum-based chemotherapy in locally advanced gastric and gastroesophageal junction adenocarcinoma: a multicenter cohort study.Frontiers in endocrinology · 2026Article
- Artificial intelligence for perioperative precision in surgical oncology.Frontiers in surgery · 2026Review
- Metabolic syndrome as an independent predictor of response and survival in locally advanced gastric cancer treated with neoadjuvant immunochemotherapy.Frontiers in oncology · 2026Article
- An integrated body composition- immunonutritional signature for predicting immunotherapy response and prognosis in gastric cancer: a multicenter retrospective cohort study.Frontiers in oncology · 2026Article
- Multimodal Artificial Intelligence-Based Virtual Biopsy for Diagnosing Abdominal Lavage Cytology-Positive Gastric Cancer.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Cytopathology 2.0: How Artificial Intelligence Is Redefining the Future of Cytopathology.Journal of cytologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
Gastric cancer with peritoneal dissemination remains a significant clinical challenge due to its poor prognosis and difficulty in early detection. This study introduces a multimodal artificial intelligence-based risk stratification assessment (RSA) model, integrating radiomic and clinical data to predict peritoneal lavage cytology-positive (GC-CY1) in gastric cancer patients. The RSA model is trained and validated across retrospective, external, and prospective cohorts. In the training cohort, the RSA model achieved an area under the curve (AUC) of 0.866, outperforming traditional clinical and radiomic feature models. External validation cohorts confirmed its robustness, with AUC values of 0.883 and 0.823 for predicting peritoneal metastasis and recurrence, respectively. In a prospective validation involving 152 patients, the model maintained superior predictive performance (AUC = 0.835). The RSA model also demonstrated significant clinical benefits by effectively identifying high-risk patients likely to benefit from specific treatments, such as paclitaxel-based conversion therapy. These findings suggest that the RSA model offers a reliable, non-invasive diagnostic tool for gastric cancer, capable of improving early detection and treatment outcomes. Further prospective studies are warranted to explore its full clinical potential.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.